1. Medtech Insight
  2. >>Minute Insights

Minute Insight: First Live Images Of Alpha-Synuclein Raise Hope For Improved Neurological Diagnostics

 
• By Barnaby Pickering

Advancements in imaging technology may bring medtech and pharma closer together and lead to better drugs for neurological conditions.

Minute Insight
• Source: Informa/Alamy

AC Immune, a Lausanne, Switzerland-based biotech company, has obtained the first non-invasive images of pathological alpha-synuclein in human brain tissue, which could lead to better therapies for neurodegenerative disease.

Alpha-synuclein is a soluble neuronal protein that is present under normal conditions as it regulates synaptic vesicle trafficking. Trafficking is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Minute Insights

Minute Insight: Haemonetics Buys OpSens To Add Fiber-Optic Sensors For Intervention

 
• By Reed Miller

Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.

Minute Insight: Best Buy Will Sell Dexcom CGM

 
• By Reed Miller

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

 
• By Barnaby Pickering

Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.

Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity

 
• By Reed Miller

Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.

More from Medtech Insight

How Notified Bodies Would Like Future EU Medtech Governance To Pan Out

 
• By Amanda Maxwell

Notified bodies are calling for their key role, as the technical, regulatory and clinical ‘extended arm’ of regulatory authorities, to remain central to the EU medtech conformity assessment process.

Thermo Fisher Margins Feel The Weight Of Tariffs Even As China Trade Pressures Ease In Q2

 
• By Shubham Singh

Thermo Fisher said the year-over-year impact of tariffs and related effects represented a 5% headwind to adjusted operating income and reduced reported margins by 140 basis points in the second quarter.

Device User Fees Up About 7% For FY2026

 
• By Elizabeth Orr

The US FDA has announced its user fees for fiscal 2026, which are based on a figure of $455,000 for a PMA.